In this context, it has been previously shown that the combination of anti-CD40 and anti-CTLA-4 antibodies accompanying a liposomal peptide or adenoviral vaccine considerably enhanced the CTL responses against tumor cells (28, 29). Here, CTLA4 is linked to neoplasm.